Filing Flows › Comparisons › EYPT vs NAUT
EyePoint vs Nautilus Biotechnology: EYPT and NAUT compared
EyePoint is the larger company: $507K of revenue in its latest quarter (Q2 2026) against $234K for Nautilus Biotechnology (Q3 2026).
Where the money goes: EYPT and NAUT
EyePoint (EYPT) · Q2 2026
EyePoint, Q2 2026: revenue $507K (-90% year over year), net loss $94.5M, operating cash flow −$62.3M. The chart follows the revenue to costs, profit and cash.
Nautilus Biotechnology (NAUT) · Q3 2026
Nautilus Biotechnology, Q3 2026: revenue $234K, net loss $15.6M, operating cash flow −$13.3M. The chart follows the revenue to costs, profit and cash.
| EyePoint (EYPT) | Nautilus Biotechnology (NAUT) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $507K | $234K |
| Revenue growth, Y/Y | -90% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$94.5M | −$15.6M |
| Operating cash flow | −$62.3M | −$13.3M |
Questions
Which is bigger, EyePoint or Nautilus Biotechnology?
EyePoint is the larger company: $507K of revenue in its latest quarter (Q2 2026) against $234K for Nautilus Biotechnology (Q3 2026).
More: EyePoint earnings · how EyePoint makes money · Nautilus Biotechnology earnings · how Nautilus Biotechnology makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 5, 2026; 10-Q filed Oct 27, 2026). Fiscal quarters can end on different dates. Not investment advice.